Short Communication: East Meets West: A Description of HIV-1 Drug Resistance Mutation Patterns of Patients Failing First Line Therapy in PEPFAR Clinics from Uganda and Nigeria

2014 ◽  
Vol 30 (8) ◽  
pp. 796-799 ◽  
Author(s):  
Keith W. Crawford ◽  
Salim Wakabi ◽  
Hannah Kibuuka ◽  
Fred Magala ◽  
Babajide Keshinro ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Short Communication ◽  
Resistance Mutation ◽  
Drug Resistance Mutation ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Hiv 1

scholarly journals Antiretroviral Drug Resistance in HIV-1–Infected Patients Experiencing Persistent Low-Level Viremia During First-Line Therapy

2011 ◽  
Vol 204 (4) ◽  
pp. 515-520 ◽  
Author(s):  
Babafemi Taiwo ◽  
Sebastien Gallien ◽  
Evgenia Aga ◽  
Heather Ribaudo ◽  
Richard Haubrich ◽  
...  
Keyword(s):  
Drug Resistance ◽  
First Line ◽  
Low Level ◽  
Antiretroviral Drug Resistance ◽  
First Line Therapy ◽  
Line Therapy ◽  
Antiretroviral Drug ◽  
Hiv 1

scholarly journals Drug resistance mutation profiles of the drug-naïve and first-line regimen-treated HIV-1-infected population of Suzhou, China

2017 ◽  
Vol 32 (4) ◽  
pp. 271-279 ◽  
Author(s):  
Tingting Li ◽  
Feng Qian ◽  
Ting Yuan ◽  
Weilu Xu ◽  
Li Zhu ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Resistance Mutation ◽  
Drug Resistance Mutation ◽  
First Line ◽  
Infected Population ◽  
Drug Naïve ◽  
Hiv 1

Patterns of imatinib resistance mutation analysis in chronic myeloid leukemia (CML) patients on imatinib at the time of loss of response to the drug in Asian Indian subjects

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 7079-7079
Author(s):  
K. Prabhash ◽  
T. Vora ◽  
N. S. Ghadyalpatil ◽  
B. Rangarajan ◽  
S. S. Hingmire ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Mutation Analysis ◽  
Resistance Mutation ◽  
The Other ◽  
Molecular Response ◽  
First Line ◽  
Imatinib Resistance ◽  
Loss Of Response ◽  
First Line Therapy ◽  
Line Therapy

7079 Background: The treatment of (CML) has undergone major changes in the past decade with the introduction of tyrosine kinase inhibitors (TKI). However the initial enthusiasm is waning with increasing recognition of drug resistance. There is an urgent need to identify the types of receptor mutations which lead to drug resistance and their significance in salvage therapy. Methods: We identified 17 males and 8 female patients with median age 40 yrs (range 9–55 years) with CML who were on imatinib at the time of loss of hematologic response (HR), cytogenetic (CyR), or molecular response (MR) and performed imatinib-resistance mutation analysis. The sequencing was done on ABI machine by direct sequencing method. Results: This group included 22 patients with chronic phase (CP) disease, 2 patients with accelerated phase (AP), and 1 patient with extramedullary blast crisis (BC). Fourteen patients received treatment with agents other than imatinib as the first-line therapy due to either nonavailability of the drug at the time of diagnosis in India, but were started on imatinib when drug became available. The other 11 patients received imatinib as first-line therapy. The best response to imatinib included major CyR in 14 patients which included 3 patients with complete CyR and minor CyR in 6 patients. Lack of HR was noted in 2 patients in whom CyR was not evaluated. Imatinib resistance mutation analysis was prompted by no HR (n = 2); loss of HR after achieving CyR (n = 9); failure to achieve CyR milestones (n = 3); loss of CyR (n = 9); development of extramedullary BC (n = 1). The analysis revealed no mutations-11 patients, M351T-4 patients, G250E-3 patients, F317L-2 patients, M244V- 1 patient, T315I-1 patient, F382L-1 patient, results awaited in 4 patients with 2 patients showing 2 mutations. Conclusions: The majority of patients 11/25 had no detectable mutations while T315I which confers resistance to all TKIs was detected only in 1/25 patients who demonstrated loss of response in our population. The correlation of the other mutations to loss of response and the response to second line TKI needs to be studied in further detail. In addition analysis of mutation patterns at baseline may help in stratifying patients for treatment. No significant financial relationships to disclose.

scholarly journals Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy

2019 ◽  
Vol 139 (4) ◽  
pp. 275-279 ◽  
Author(s):  
Xiao-lu Luo ◽  
Li-da Mo ◽  
Guo-sheng Su ◽  
Jin-ping Huang ◽  
Jing-yu Wu ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Resistance Mutation ◽  
Drug Resistance Mutation ◽  
First Line ◽  
Hiv 1

Short Communication: HIV-1 Drug Resistance Mutation Analyses of Cameroon-Derived Integrase Sequences

2021 ◽  
Vol 37 (1) ◽  
pp. 54-56
Author(s):  
Sello Given Mikasi ◽  
Darren Isaacs ◽  
George Mondinde Ikomey ◽  
Henerico Shimba ◽  
Ruben Cloete ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Short Communication ◽  
Resistance Mutation ◽  
Drug Resistance Mutation ◽  
Hiv 1 ◽  
Mutation Analyses

scholarly journals Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap–Core Interface of HIV-1 Protease

ACS Omega ◽  
2018 ◽  
Vol 3 (9) ◽  
pp. 12132-12140 ◽  
Author(s):  
Andres Wong-Sam ◽  
Yuan-Fang Wang ◽  
Ying Zhang ◽  
Arun K. Ghosh ◽  
Robert W. Harrison ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Resistance Mutation ◽  
Drug Resistance Mutation ◽  
Hiv 1

scholarly journals Impact of HIV Type 1 Subtype on Drug Resistance Mutations in Nigerian Patients Failing First-Line Therapy

2011 ◽  
Vol 27 (1) ◽  
pp. 71-80 ◽  
Author(s):  
B. Chaplin ◽  
G. Eisen ◽  
J. Idoko ◽  
D. Onwujekwe ◽  
E. Idigbe ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Resistance Mutations ◽  
First Line ◽  
Drug Resistance Mutations ◽  
First Line Therapy ◽  
Line Therapy ◽  
Hiv Type 1

scholarly journals Monitoring of HIV Drug Resistance Mutations in Newly Diagnosed Patients in Cyprus (2010–2012)

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S424-S424
Author(s):  
Ioannis Demetriades
Keyword(s):  
Drug Resistance ◽  
Phylogenetic Trees ◽  
Resistance Mutation ◽  
Drug Resistance Mutation ◽  
High Rate ◽  
Resistance Testing ◽  
Newly Diagnosed ◽  
Resistance Mutations ◽  
Subtype B ◽  
Hiv 1

Abstract Background A molecular epidemiology study of HIV-1 infection was conducted in 100 HIV-1 diagnosed and untreated patients in Cyprus representing 65.4 percent of all the reported HIV-1 infections in Cyprus between 2010 and 2012. Methods Eighty-two patients were newly diagnosed (genotypic drug resistance testing within six months from diagnosis), and 18 patients were HIV-1 diagnosed for a longer period or the diagnosis date was unknown. Results Phylogenetic trees of the pol sequences obtained in this study with reference sequences indicated that subtypes B and A1 were the most common subtypes present and accounted for 41.0 and 19.0% respectively, followed by subtype C (7.0%), F1 (8.0%), CRF02_AG (4.0%), A2 (2.0%), other CRFs (7.0%) and unknown recombinant forms, URFs (12%). Most of newly-diagnosed study subjects were Cypriots (63%), males (78%) with median age 39 (Interquartile Range, IQR 33–48) reporting having sex with other men, MSM (51%). Conclusion A high rate of clustered transmission of subtype B drug-sensitive strains to reverse transcriptase and protease inhibitors was observed among MSM. Twenty-eight out of forty-one MSM study subjects (68.0%) infected were implicated in five transmission clusters, two of which are subtype A1 and three subtype B strains. The two largest MSM subtype B clusters included nine and eight Cypriot men, respectively, living in all major cities in Cyprus. There were only three newly diagnosed patients with transmitted drug resistant HIV-1 strains, one study subject from the United Kingdom infected with subtype B strain and one from Romania with subtype A2 strain, both with the PI drug resistance mutation M46L and one patient from Greece with subtype A1 strain with the NNRTI drug resistance mutation K103N. Disclosures All authors: No reported disclosures.

Sign in / Sign up

Export Citation Format

Share Document